Two orthopedic companies, Arthrex Inc. and Xtant Medical Holdings, Inc. signed distribution agreements with Vivex Biomedical, Inc. in March to give them access to the biomedical company’s proprietary line of biologics.
Vivex Biomedical Signs Deals with Arthrex and Xtant Medical
1 min read Premium comments
Secondary
The March 31, 2016 agreement with Arthrex, “significantly” expands the breadth of Vivex Biomedical products available through Arthrex. The March 24 agreement between Xtant Medical and Vivex Biomedical will allow Xtant Medical to immediately enter the cellular bone graft market with a viable cell allograft, OsteoVive.
According to BioMedGPS, LLC, it estimates the cellular allograft market was approximately $252 million in 2015, and is anticipated to be near $400 million in 2019, making it the fastest growing segment of the bone replacement market.
“We are pleased to be adding this distinguished viable cell allograft to our biologic portfolio, ” said Dan Goldberger, CEO of Xtant Medical. “The addition of OsteoVive will allow us to better meet the preferences of our surgeons, and will increase the value we are able to deliver to our customers.”
The expanded relationship with Arthrex builds on years of developing and distributing BioCartilage by Arthrex and Vivex through their University of Miami Tissue Bank. BioCartilage serves as a scaffold over a microfractured defect, and provides a tissue network that can potentially signal autologous cellular interactions and improve the degree and quality of tissue healing within a properly prepared articular cartilage defect.
“As with BioCartilage, the continued partnership between Arthrex and Vivex Biomedical will support the further development and distribution of quality orthobiologic technologies, ” said David Shepard, director of Orthobiologics at Arthrex.
Vivex Biomedical is based in Marietta, Georgia, and is privately held. The company focuses on cellular therapies that treat orthopedic, spine, wound and soft tissue indications. The company holds exclusive rights to proprietary technologies in the fields of biomedicine, stem cells, and orthopedic implant surface modification. Technologies include marrow isolated adult multilineage inducible (MIAMI) cell identification and processing, as well as mimetic patterning technologies (MIME) which, according to the company, can improve the efficiency and efficacy of a patient’s healing cascade and reduce the overall cost of healthcare.
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.